Melacine (melanoma vaccine) / GSK - LARVOL DELTA

Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival (Cancer Immunol Res) - P3, N=689; SWOG-9035; “Among the subpopulation with HLA A2 and/or HLA Cw3 serotype, vaccine arm patients (n=178) had marginally improved RFS (adjusted P=.02) and significantly improved OS compared with observation arm patients (n=145), with 10-year OS of 75% and 63%, respectively (hazard ratio 0.62, 99% CI 0.37-1.02, P=.01). There was no impact of HLA A2 and/or HLA Cw3 expression among observation arm patients.”

P3 data • Melanoma